C
Charles A. Morris
Researcher at Brigham and Women's Hospital
Publications - 41
Citations - 4288
Charles A. Morris is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 18, co-authored 37 publications receiving 3902 citations. Previous affiliations of Charles A. Morris include AstraZeneca & Office of the Attorney General.
Papers
More filters
Journal ArticleDOI
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
Malcolm R Ranson,Lisa A. Hammond,David Ferry,Mark G. Kris,Andrew Tullo,Philip I. Murray,Vince Miller,Steven D. Averbuch,Judith Ochs,Charles A. Morris,A. Feyereislova,Helen Swaisland,Eric K. Rowinsky +12 more
TL;DR: ZD 1839 was well tolerated, with DLT observed at a dose well above that at which antitumor activity was seen, and Pharmacokinetic analysis confirmed that ZD1839 was suitable for administration as a once-daily oral tablet formulation.
Journal ArticleDOI
Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment
Anthony Howell,John F.R. Robertson,J Quaresma Albano,A. Aschermannova,L. Mauriac,Ulrich R. Kleeberg,Ignace Vergote,B Erikstein,Alan Webster,Charles A. Morris +9 more
TL;DR: Fulvestrant is an additional, effective, and well-tolerated treatment for advanced breast cancer in postmenopausal women whose disease progressed on prior endocrine therapy.
Journal ArticleDOI
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Anthony Howell,John F.R. Robertson,Paul Abram,Mikhail Lichinitser,Richard M Elledge,Emilio Bajetta,Toru Watanabe,Charles A. Morris,Alan Webster,Isaiah W. Dimery,C. Kent Osborne +10 more
TL;DR: In the overall population, between-group differences in efficacy end points favored tamoxifen, and statistical noninferiority of fulvestrant could not be demonstrated, but in patients with hormone receptor-positive tumors, fulvestant had similar efficacy to tamoxIFen and was well tolerated.
Journal ArticleDOI
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
TL;DR: ICI 182,780 (Faslodex™) from AstraZeneca (Cheshire, United Kingdom) is a novel, steroidal estrogen antagonist that was designed to be devoid of estrogen agonist activity in preclinical models as discussed by the authors.
Journal ArticleDOI
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
John F.R. Robertson,C. Kent Osborne,Anthony Howell,Stephen E. Jones,Louis Mauriac,Matthew J. Ellis,Ulrich R. Kleeberg,Steven E. Come,Ignace Vergote,Stan Gertler,Aman U. Buzdar,Alan Webster,Charles A. Morris +12 more
TL;DR: The authors report the prospectively planned combined analysis of data from 2 Phase III trials comparing fulvestrant 250 mg monthly and anastrozole 1 mg daily in postmenopausal women with advanced breast carcinoma who previously had progressed after receiving endocrine treatment.